Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC
NCT ID: NCT05969418
Last Updated: 2024-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2023-07-01
2023-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research of Automated Maculopathy Screening Based on AI Techniques Using OCT Images
NCT03476291
OCTA and Retinal Angiomatous Proliferation
NCT04689789
Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients
NCT06084650
High-throughput Large-model-based AI-assisted Diagnosis Using OCT
NCT07249307
Deep Learning for Fluorescein Angiography and Optical Coherence Tomography Macular Thickness Map Image Translation
NCT05105620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study evaluates the changes in structural optical coherence tomography and optical coherence tomography angiography features in neovascular macular degeration patients undergoing ANTI-VEGF treatments using artificial intelligence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with neovascular macular degeneration
Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
healty patients matched age and sex without any ocular disease
Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* absence of previous retinal surgery and congenital eye diseases.
* absence of errors of refraction
* absence of lens opacities
* absence of low-quality OCT and OCTA images
Exclusion Criteria
* errors of refraction
* lens opacities
* low-quality OCT and OCTA images
50 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federico II University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gilda Cennamo
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ciro Costagliola, MD
Role: STUDY_CHAIR
Federico II University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federico II University
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05809850
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.